Regenerative Medicine Market Research Report with Latest Trend, Share, Size, Opportunities For $ 17.9 billion Industry

The Regenerative Medicine Market growth is driven by rising investments in regenerative medicine research, and the growing pipeline of regenerative medicine products, and the increase in prevalence of chronic diseases, genetic disorders, and cancer.

Growing prevalence of chronic diseases, genetic disorders, and cancer;

Over the last few decades, the incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe. Diabetes and obesity can result in the increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, which require treatments and incur exorbitant medical expenses.

Opportunity: Implementation of the 21st Century Cures Act;

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation and covers various provisions that may impact the development and approval of several products in the coming years.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

Regenerative Medicine Market

The tissue-engineered products segment accounted for the largest share of the Regenerative Medicine Market.

Based on products, segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The tissue-engineered products segment accounted for the largest share in the market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment to register the highest growth rate during the forecast period

Based on applications, the Regenerative Medicine Market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579

Recent Developments:

– In February 2020, Integra Lifesciences (US) launched AmnioExcel Plus Placental allograft membrane.

– In November 2019, Stryker Corporation (US) acquired Wright Medical (US) to strengthen its product portfolio.

– In March 2019, Smith & Nephew (UK) acquired Osiris Therapeutics (US) to strengthen its product portfolio.

North America is the largest regional market for Regenerative Medicine Market

The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the market. The growth in the North American market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The major players operating in this Regenerative Medicine Market are 3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US).

Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=65442579

Contract Research Organization Services Market – Developing Regions is Well-Positioned for Strong Growth in the Coming Years

The Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0 % during the forecast period.

Increasing investment in pharmaceutical R&D:

Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharmaceutical companies are increasing their R&D efficiencies through heavy investments in R&D and through collaborative R&D efforts. According to the EvaluatePharma report, the global pharmaceutical R&D spending was valued at USD 137 billion in 2012; this increased to USD 212 billion in 2021 and is projected to reach USD 254 billion by 2026. As per the report, R&D spending is observed to be growing steadily at a CAGR of 4.2% from 2020 to 2026. This is expected to boost the outsourcing of research services by pharmaceutical companies, biotechnology companies, as well as research and academic organizations.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167410116

Contract Research Organization (CROs) Services Market

Growth in the drugs and biologics market despite the COVID-19 pandemic:

Despite the ongoing COVID-19 pandemic, 2020 has been the second-best year for the pharmaceutical industry in terms of the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 comprised 40 new chemical entities and 13 biologics. The approved biologics included 10 monoclonal antibodies, 2 antibody-drug conjugates, 3 peptides, and 2 oligonucleotides. The FDA has authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010. This growth in the number of approved products worldwide is attributed to the rising investments by biopharmaceutical companies to develop biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical product sales in 2022.

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021.

Based on type, the Contract Research Organization Services Market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.  

The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021. 

Based on therapeutic area, the Contract Research Organization (CROs) Services Market is segmented into oncology, infectious diseases, neurology, vaccines, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the global Contract Research Organization Services Market in 2021. The large share of this segment is primarily attributed to the increasing number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.

Request Sample Pages: 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=167410116

The Asia Pacific region is the fastest-growing region of the CRO services market in 2021.

Based on the region The global Contract Research Organization (CROs) Services Market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The market in the Asia Pacific is estimated to record the highest CAGR during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, increasing number of pharmaceutical companies establishing their manufacturing facilities in the region, and the lower cost of clinical trials in the region.

Key players in the Contract Research Organization Services Market include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (Now a part of Thermo Fisher Scientific Inc.) (US), ICON plc (Ireland), Syneos Health, Inc. (US), Parexel International Corporation (US), and Charles River Laboratories International Inc. (US)

Speak to Analyst: 
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=167410116

Virology Specimen Collection Market – Emerging Industry Trends and Global Future Forecast

The Growth in Virology Specimen Collection Market is mainly driven by the rising prevalence of viral diseases, the increasing prevalence of human papillomavirus (HPV) and cervical cancer, and the growing number of blood donations.

Rising prevalence of viral diseases and emergence of newer pathogens:

The Zika virus and Babesia outbreaks, alongside announcements for their inclusion in virology specimen collection tests, indicate the need for innovation in virology specimen collection technologies, consumables, and instruments. Other countries have also undertaken initiatives to check for new and emerging diseases. For example, the prevalence of malaria in African regions and the possibility of mosquito-borne transfer of Zika has resulted in mandates for Zika virus screening in the region.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150226807

This research study involved four major activities in estimating the current size of the virology specimen collection market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

The viral transport media segment accounted for the largest share of the specimen collection market, by product segment, in 2020

Based on product, the virology specimen collection market is segmented into blood collection kits, specimen collection tubes, viral transport media and swabs. The viral transport media segment accounted for the largest share of the market in 2020. Factors such as rising prevalence of viral diseases and emergence of newer pathogens are contributing for the growth of this market.

Blood segment to register the highest growth rate during the forecast period

The virology specimen collection market is segmented into blood, nasopharyngeal, nasal, throat, cervical, oral and other samples. In 2020, the blood segment accounted for the highest growth rate. Factors such as the rising number of blood donations and rising prevalence of viral diseases and emergence of newer pathogens.

Request Sample Pages: 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150226807

Geographically: The global Virology Specimen Collection Market is segmented into four major regions, namely, North America, Europe, the Asia Pacific and Rest of the World. In 2020, North America accounted for the largest share of the market. The large share of this region can be attributed to increasing number of blood donations in the region.

The major players operating in virology specimen collection market are Becton, Dickinson and Company (US), Quidel Corporation (US), Thermo Fisher Scientific, Inc. (US), Trinity Biotech (Ireland), Titan Biotech, Ltd. (India), Diasorin SA (Italy), Vircell S.L. (Spain), Copan Italia S.p.A. (Italy), Puritan Medical Products, Co. (Guilford, ME) and Hardy Diagnostics (US).

Speak to Analyst: 
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=150226807

Aptamers Market – Segmentation, Geographical Analysis & Major Key Players

Growth Factors Driving the Market: The Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.

MarketsandMarkets™ View on Revenue: The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.

aptamers market

Industry Segmentation in Detailed:

“The therapeutics development segment will continue to dominate the aptamers application market during the forecast period”

Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.

“Pharmaceutical & biotechnology companies are the largest end users of aptamers technology”

Based on end user, the global aptamers market is segmented into pharmaceutical companies & biotechnology companies, academic & government research institutes, contract research organizations, and other end users. In 2020, pharmaceutical & biotechnology companies dominated the market owing to the increasing number of market players offering custom aptamers for use in therapeutics development & rising R&D expenditure. The diagnostic segment will record the highest CAGR during the forecast period due to the development of diagnostic tools for cancer and infectious diseases.

“The DNA-based aptamers segment will continue to dominate the aptamers type market during the forecast period”

Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167

Leading Key Players Analysis:

Some of the key players operating in the aptamers technology market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US) among others.

Geographical Trends in Detailed:

The global aptamers market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of this market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1167

Orthodontic Supplies Market Growth and key Industry Players, Analysis and Forecast

According to the new market research report “Orthodontic Supplies Market by Product (Braces (Removable, Fixed), Brackets (Ligating, Lingual, Metal), Archwires (Ni-Ti, steel), Anchorage, Ligature(Elastomeric, wire), Patient(Adult, Children), Users(Hospitals, Clinics, OTC) – Global Forecast to 2026″, published by MarketsandMarkets™, the Orthodontic Products Market is projected to reach USD 8.3 billion by 2026 from USD 5.4 billion in 2021, at a CAGR of 9.1% during the forecast period.

Opportunity: Emerging markets in APAC and RoW;

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the orthodontic supplies market. Growth in these markets can be attributed to the presence of a large patient population, rising disposable incomes among the middle-class population, and the increasing focus of public and private organizations on increasing the awareness about orthodontic treatments and dental hygiene. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers.

Along with this, many players are focusing on strategic investments to develop end-to-end digital software solutions with 3D digital scanning, diagnostics, outcome visualization, treatment planning, custom appliances, and custom lab products. For instance, in September 2020, Light Force Orthodontics, a manufacturer of customizable 3D-printed bracket systems, raised USD 14 million from Series B round led by Tyche Partners with follow-on investment from Matrix Partners and AM Ventures.

This 3D printing technology helps to create customized braces for each patient. This plays a critical role in significantly reducing the number of visits to orthodontic clinics for the adjustment of braces. These developments are expected to provide a wide range of opportunities for players to capture a large customer base in the orthopedic supplies market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=236529189

The Increasing prevalence of malocclusion, rising emphasis on effective orthodontic treatment and t the initiatives undertaken by governments to increase the awareness about orthodontic treatments are fueling the demand for orthodontic supplies during the forecast period.

The orthodontic supplies market includes major Tier I and II suppliers of orthodontic products are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), American Orthodontics (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), Morelli Orthodontics (Brazil), ClearCorrect (US), and Ultradent Products (US).

These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Due to the pandemic, the orthodontic supplies market experienced short-term negative growth, which can be attributed to a sharp reduction in access to hospital and dental clinics and the temporarily shutdown of orthodontic clinics.

Orthodontic practices around the globe are facing challenges amid the pandemic. The adoption of strict protocols outside and inside dental clinics, increasing usage of teleorthodontics in case of urgent appointments, and opting for minimal orthodontic treatment procedures by many orthodontic clinics are likely to have a positive impact on the market. Moreover, post lockdown, as dental practices reopen, it is expected that patient volumes are anticipated to rebound at a higher pace.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=236529189

Demand for invisible braces among the target population due to their aesthetic benefits drives the growth of removable braces

Removable braces offer advantages over traditional braces, including easy removal of braces, reduced risk of periodontal diseases & tooth decay, and enhanced comfort. Factors such as strong focus on product innovation by players and growing awareness about the benefits associated with removable braces and the growing demand for invisible braces among teens and adults due to their aesthetic benefits is augumenting the growth of removable braces.

Asia Pacific likely to emerge as the fastest growing orthodontic supplies market, globally

Geographically, the emerging Asian countries, such as China, India, Japan and Singapore, are offering high-growth opportunities for market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 10.8% from 2021 to 2026. Expansion of healthcare infrastructure and increase in disposable personal income, increase patient population with malocclusion and tooth decay are factors likely to support the growth of market in the region. Moreover, the growing focus toward aesthetics products among adults and emergence of small manufacturers in the market are driving the growth of the APAC orthodontic supplies market.

Prominent players in this market are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), among others.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=236529189

Central Fill Pharmacy Automation Market – Anticipated To Witness High Growth In The Near Future

According to the new market research report “Central Fill Pharmacy Automation Market by Product (Equipment (Medication Dispensing System, Automated Medication Compounding Systems, Workflow Management), Service (Process Optimization, Facility Design), Software), Vendor – Global Forecast to 2024″, published by MarketsandMarkets™, the Pharmacy Automation Market is projected to reach USD 656 million by 2024 from USD 381 million in 2019, at a CAGR of 11.5%.

Recent Developments;

– In 2018, TCGRx acquired Parata Systems, to expand the company’s existing growth initiatives with central fill, inventory control, and automated blister card packaging technologies.

– In 2018, ARxIUM, Inc., launched cGMP RIVA IV Compounding system for 503B facilities.

– In 2018, Swisslog Healthcare acquired Talyst Systems, LLC. With the aim of expanding Swisslog’s inpatient and outpatient pharmacy solutions along with the company’s field service network.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87188549

The increasing demand for specialty drugs being dispensed by central fill pharmacies is one of the primary drivers propelling the growth of this market. Other factors such as the need to minimize medication errors, growing patient volume (which in turn is increasing the burden on pharmacies), and the growing focus on automation to reduce labor costs are also driving market growth.

The equipment segment is expected to account for the largest share of the pharmacy automation market

The central fill pharmacy automation market, by product and service, is segmented into equipment, services, and software. The equipment segment accounted for the largest market share in 2018. A number of automated systems are used in facilities offering the advantages of freeing up manpower, allowing greater throughput, and increasing the number of processed prescriptions. These facilities form an indispensable tool for central fill pharmacies to improve the prescription assembly, verification, and delivery back to the pharmacy. This contributes to the large share of the segment.

The equipment vendors are increasing with the increasing demand for automation systems

Based on vendor, the central fill pharmacy automation market is segmented into equipment vendors and consulting vendors. The equipment vendors segment is estimated to account for the largest market share in 2018. This is mainly attributed to their broad product portfolio, vast geographic presence, strong technical expertise, and easy access to spare parts (resulting in reduced downtime).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=87188549

North America is expected to dominate the pharmacy automation market during the forecast period

In 2018, North America dominated the central fill pharmacy automation market, followed by Europe, and this trend is expected to continue during the forecast period. The rising focus on providing value-based care to patients, increase in specialty medication dispensing, growing number of medication errors, and the need for automated systems for improved compounding and dispensing are major factors that have resulted in the increased adoption of central fill pharmacy automation equipment and services in North America.

Prominent players in the central fill pharmacy automation market are ARxIUM, Inc. (US), RxSafe, LLC (US), TCGRX Pharmacy Workflow Solutions (US), McKesson Corporation (US), Omnicell, Inc. (US), ScriptPro (US), Kuka AG (Germany), Innovation (US), R/X Automation Solutions (US), Tension Packaging & Automation (US), Cornerstone Automation Systems, LLC (CASI, US), and QMSI (US)

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=87188549

2022 Global Biobanking Market Report- Opportunities in Future with Different Segments

According to the new market research report “Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) – Global Forecast”, published by MarketsandMarkets™, the biobanking devices market is expected to reach USD 2.69 Billion by 2022 from USD 1.85 Billion in 2017, at a CAGR of 7.8%.

Regenerative medicine applications for biobanking market will drive the market;

The Biobanking Devices Market plays an integral role in advancing biomedical and translational research, through the collection and preservation of biological samples, such as blood, tissues, and nucleic acids, which are then made available for use in research to discover disease-relevant biomarkers; this is further used for diagnosis, prognosis, and predicting drug responses. Growth in the number of research activities in this segment forms a major driver for the market. The availability of government funding for regenerative medicine, stem cell therapeutics, and cell & gene therapy is supporting research activities in this segment. Apart from this, the increasing trend of cord blood banking will also aid growth of this market segment. Future prospects including advancements in orthopedic procedures with the use of stem cells are expected to further support market growth for regenerative medicine.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594

Biobanking Market

The Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research; and the growing need for cost-effective drug discovery and development.

The equipment segment is expected to dominate the biobanking devices market.

By product and service, the biobanking market is segmented into equipment, consumables, services, and software. The equipment segment is expected to dominate the global market in 2017. Rising number of biobanks and the increasing number of biospecimens are factors increasing the demand for biobanking equipment.

Blood products are estimated to command the largest biobanking devices market share.

The biobanking market is segmented by sample type into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. In 2017, the blood products segment is expected to account for the largest share of the market, by sample type. Rising incidence of blood disorders and the increasing demand for various types of blood products across the globe are driving the growth of this segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=594

North America is expected to account for the largest share of the biobanking devices market.

Based on region, the biobanking market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is expected to dominate the market in 2017, this is attributed to factors like increasing research activities in regenerative medicine, cell and gene therapy; growing interest in personalized medicine and biomarker discovery; increasing number of biotechnology and pharmaceutical companies; and rising investments in genomics and proteomics research in the region as compared to other regions.

Key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=594

Antares Vision (Italy), OPTEL Vision (Canada) are Prominent Players in the Track and Trace Solutions Market

According to the new market research report “Track and Trace Solutions Market by Product (Plant Manager, Checkweigher, Barcode Scanner, Monitoring), Technology (2D Barcode, RFID), Application (Serialization, Aggregation, Reporting), End User (Pharma, Food, Medical Devices) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 7.3 billion by 2026 from USD 4.1 billion in 2021, at a CAGR of 12.1% during the forecast period.

Opportunities: Remote authentication of products;

Traditional brand protection technologies such as anti-theft and authentication are intended to protect individual items rather than safeguard the entire supply chain. There is a high possibility of fake products being introduced at any stage in the supply chain. To combat counterfeiting and identify massive product items, a solution with automatic and non-line-of-sight capabilities is required. The demand for technologies with modular designs, which fit enterprise needs, has increased in the last few years. For instance, track and trace technologies based on RFID maintain an electronic pedigree that records the transaction information of products within the supply chain. This approach proved to be a standout for protecting the supply chain against infiltration, theft, and fraud and supporting remote authentication in the brand protection supply chain. Technologies that are scalable from a single production line to a multi-facility/multi-line infrastructure while minimizing the initial investment are projected to gain attention in the coming future.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158898570

“The Software segment accounted for the largest market share in 2020.”

Based on products, the market is segmented into software, hardware components, and standalone platforms based on product. The software segment accounted for the largest share—60.1%—of the track and trace solutions market in 2020. Market growth is largely driven by the increasing awareness about secure packaging, the rising number of counterfeit drugs and related products, and growing awareness of brand protection. In addition, regulatory compliance is further supporting the growth of this market.

The standalone platforms segment is expected to register the highest CAGR of 15.9% during the forecast period. The growth in this market is mainly attributed to the stringent government regulations for implementing serialization and UDI codes in the pharma and medical device industry, increasing pressure on pharmaceutical companies to adopt serialization, and increasing demand for standalone platforms to reduce the serialization implementation timeframe.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=158898570

“The Serialization solutions segment accounted for the largest market share in 2020.”

Based on application, the track and trace solutions market is segmented into serialization solutions; aggregation solutions; and tracking, tracing, and reporting. The serialization solutions segment accounted for the largest share—62.3%—of the applications market. This segment is projected to grow at a CAGR of 12.0% during the forecast period to reach USD 2,560.9 million by 2026. Stringent regulations for the implementation of serialization solutions in packaging and supply chain applications drive this segments growth.

The tracking, tracing and reporting segment is expected to register the highest CAGR of 16.1% during the forecast period owing to the increasing number of regulations such as DSCSA, UDI, and Medical Device Reporting (MDR) for medical devices and pharmaceutical products.

“The 2D Barcode segment accounted for the largest market share in 2020.”

Based on technology, the track and trace solutions market is segmented into linear barcodes, 2D barcodes, and radiofrequency identification (RFID). The 2D barcodes segment accounted for the largest share of 76.2% of the technology market in 2020. This segment is projected to grow at a CAGR of 12.4% to reach USD 5,641.3 million by 2026. The large share of the 2D barcodes technology segment can be attributed to the increasing use of 2D barcodes in the packaging industry. They have higher data storage capacities than linear barcodes and contain larger amounts of data with fewer variations in image size.

The RFID segment is expected to register the highest CAGR of 13.7% during the forecast period due to the growing demand for these systems in automated pharmaceutical distribution and medical devices due to low labor costs and improved visibility & planning.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=158898570

“The Pharmaceutical and Biopharmaceutical Company segment accounted for the largest market share in 2020.”

Based on technology, the track and trace solutions market is segmented into linear barcodes, 2D barcodes, and radiofrequency identification (RFID). The 2D barcodes segment accounted for the largest share of 76.2% of the technology market in 2020. This segment is projected to grow at a CAGR of 12.4% to reach USD 5,641.3 million by 2026. The large share of the 2D barcodes technology segment can be attributed to the increasing use of 2D barcodes in the packaging industry. They have higher data storage capacities than linear barcodes and contain larger amounts of data with fewer variations in image size.

The RFID segment is expected to register the highest CAGR of 13.7% during the forecast period due to the growing demand for these systems in automated pharmaceutical distribution and medical devices due to low labor costs and improved visibility & planning.

“North America was the largest regional market for track and trace solutions market in 2020”

Geographically; divided into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 42.9% of the global market, followed by Europe (33.5%). The presence of developed healthcare systems in the US & Canada; the presence of many pharmaceutical & biotechnology companies and medical device manufacturers; stringent regulations regarding serialization; and the growing medical devices market are major factors driving market growth in North America.

Asia Pacific (APAC) is the fastest-growing market and is projected to grow at the highest CAGR of 13.8% for track and trace solutions. Growing regulatory requirements in the healthcare industry to comply with manufacturing and distribution practices, the rising number of pharmaceutical and biotechnology companies, and the significant economic development in emerging Asia Pacific countries such as China and India are the major factors driving the demand for track and trace solutions in the APAC region.

Some of the prominent players in the track and trace solutions market are OPTEL GROUP (Canada), Mettler-Toledo International Inc. (US), Systech International Inc. (US), TraceLink Inc. (US), Antares Vision (Italy), SAP (US), Xyntek Inc. (US), SEA Vision Srl (Italy), Syntegon (Germany), Körber Medipak Systems AG (Switzerland), Siemens AG (Germany), Uhlmann Group (Germany), JEKSON VISION (India), Videojet Technologies, Inc. (US), Zebra Technologies Corporation (US), Axway Inc. (US), ACG Worldwide (India), Laetus GmbH (Germany), and WIPOTEC-OCS (Germany).

Research Report on Viral Clearance Market Globally strategic overview

According to the new market research report “Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) – Global Forecast”, published by MarketsandMarkets™, is expected to reach USD 724.5 million, nearly at a CAGR of 21.7% during the forecast period.

Objectives of the Study;

• To define, measure, and describe the global viral clearance market by application, method, end user, and region
• To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197

The recombinant proteins segment is expected to account for the largest share.

On the basis of application, is segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the viral clearance market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules. Furthermore, the regulatory requirement to demonstrate the capacity of the purification process to effectively clear infectious viruses during the manufacturing of recombinant proteins is also expected to support the growth of this market segment during the forecast period.

The pharmaceutical & biotechnology companies segment is expected to account for the largest share.

By end user, the viral clearance market is segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. In 2018, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the rapid expansion of the biopharmaceutical industry, growth in the number of research activities in life sciences, increasing R&D investments in drug development, and increasing number of drug launches.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=62681197

Geographically; the North American region is expected to account for the largest share of the market in 2018. The viral clearance market in the region is driven by the presence of national institutes supporting biotechnology and life science research, growth in the pharmaceuticals industry, and the increasing number of drug approvals.

However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).

Merck KGaA (Germany) is one of the leading players in the viral clearance market. The company’s Process Solutions business unit offers over 15,000 products and services including single-use manufacturing, filtration, chromatography, purification, virus reduction, drug delivery compounds, and engineering and validation services. R&D is a key area of focus for Merck-it invested USD 272.3 million in R&D activities in 2017. The company strives to expand its product portfolio, build a better network for increasing its customer base, and enter new markets. The company mainly focuses on achieving organic growth to expand its geographic presence in international markets.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=62681197

Cell Culture Media Market – Insights and In Depth Analysis of Industry Segments and Key Players

According to the new market research report “Cell Culture Media Market by Type(Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application(Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User(Pharma, Biotech) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 10.3 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 16.0% between 2021 and 2026.

Browse in-depth TOC on “Cell Culture Media Market”
314 – Tables
41 – Figures
303 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97468536

Cell Culture Media Market

The global cell culture media market is expected to grow at a CAGR of 16.0% during the forecast period. The growth of this market is majorly driven by the rising R&D spending in pharmaceutical companies, emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. On the other hand, expensive cell biology research products and ethical concerns regarding cell biology research are expected to hinder the growth of this market.

The serum-free media segment accounted for the largest share of the type segment in the cell culture media market in 2020.

Based on type, the market is segmented into serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2020, the serum-free media segment accounted for the largest share of the market. This can be attributed to the advantages of serum-free media over other types of media, including consistent performance, increased growth & productivity, better control over physiological responsiveness, and reduced risk of contamination by serum-borne adventitious agents in cell culture.

The biopharmaceutical production segment accounted for the largest share of the application segment in the cell culture media market in 2020.

Based on application, the market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is further divided into monoclonal antibody production, vaccine production, and other therapeutic protein production. The tissue engineering & regenerative medicine segment is further divided into cell & gene therapy and other tissue engineering & regenerative medicine applications. The biopharmaceutical production segment is estimated to grow at the highest CAGR of 17.5% during the forecast period. The high growth of this segment is attributed to the commercial expansion of major pharmaceutical and biotechnology companies, the increasing demand for mAbs, and the growing regulatory approvals for the production of cell culture-based vaccines.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=97468536

The Asia Pacific region is the fastest-growing region of the cell culture media market in 2020.

Based on the region, the global market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to register the highest CAGR during the forecast period. The growing geriatric population, favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian economies are the major factors contributing to the growth of the cell culture media market in the Asia Pacific.

Key players in the cell culture media market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany), Corning Incorporated (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=97468536